Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion
- Sponsor
- Al-Azhar University
- Study ID
- NCT06146309
- Status
- Completed
Conditions
- Branch Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 47 Years - 68 Years
- Healthy Volunteers
- Accepted
Interventions
- aflibercept (2mg/0.05ml) — DRUGAflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy. It is in the vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) antagonist class of medications. Aflibercept acts as a soluble protein decoy for VEGF receptors to inhibit the predominant signaling pathway responsible for angiogenesis and vascular leakage. Aflibercept and other anti-VEGF inhibitors have become the gold standard in controlling neovascular (wet) age-related macular degeneration (NVAMD). T
Study Details
Several studies have indicated a relation between the development of RVO and elevated intraocular pressure (IOP) and glaucoma \[9\]. Further investigations into the structural alterations in the fellow eyes of individuals with unilateral RVO have revealed that the pRNFL is thinner than in healthy eyes, suggesting that there may be systemic risk factors for both RVO and glaucoma
Key Dates
- Start date
- Dec 1, 2020
- Status verified
- Nov 2023
- Primary completion
- Jul 20, 2022
- Completion
- Aug 1, 2022
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Patients with unilateral BRVO
- No Intervention: Healthy individuals
Primary Outcome Measure
peri-papillary retinal nerve fiber layer thickness [ Time Frame: Base line ]